Coya Therapeutics, Inc. (NASDAQ:COYA) Receives $15.33 Consensus Price Target from Analysts

Coya Therapeutics, Inc. (NASDAQ:COYA) has received a consensus rating of “Moderate Buy” from the seven research firms that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. The average 12 month target price among brokers that have covered the stock in the last year is $15.3333.

Several equities analysts recently issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Coya Therapeutics in a report on Friday, July 17th. HC Wainwright reissued a “buy” rating on shares of Coya Therapeutics in a report on Monday. Chardan Capital restated a “buy” rating and set a $14.00 target price on shares of Coya Therapeutics in a research report on Wednesday, August 12th. Roth Capital reaffirmed a “buy” rating and issued a $12.00 target price on shares of Coya Therapeutics in a research note on Monday. Finally, Wall Street Zen cut shares of Coya Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th.

Institutional Trading of Coya Therapeutics

A number of institutional investors have recently bought and sold shares of the business. JPMorgan Chase & Co. bought a new stake in shares of Coya Therapeutics during the 3rd quarter valued at $28,000. CIBC Private Wealth Group LLC bought a new position in shares of Coya Therapeutics in the 4th quarter worth $47,000. Occudo Quantitative Strategies LP acquired a new stake in shares of Coya Therapeutics during the fourth quarter worth $66,000. Oppenheimer & Co. Inc. acquired a new stake in shares of Coya Therapeutics during the fourth quarter worth $81,000. Finally, AXQ Capital LP bought a new stake in Coya Therapeutics in the second quarter valued at about $116,000. Institutional investors and hedge funds own 39.75% of the company’s stock.

Coya Therapeutics News Summary

Here are the key news stories impacting Coya Therapeutics this week:

• Positive Sentiment: HC Wainwright maintained a “Buy” rating and raised several forecasts. The firm improved its FY2026 EPS estimate to a loss of $1.30 from $1.52, raised Q3 2026 EPS to a loss of $0.33 from $0.40, and increased its Q4 2026 estimate to a loss of $0.36 from $0.44. FY2027 expectations also improved modestly to a loss of $1.64 from $1.66. These revisions suggest analysts see somewhat lower operating losses than previously expected. HC Wainwright estimate revisions
• Positive Sentiment: Analysts assigned COYA an average price target of $15.33, substantially above the current trading range. While price targets can be speculative for an early-stage biotechnology company, the gap indicates significant potential upside if Coya advances its pipeline and improves its financial outlook. Coya Therapeutics receives $15.33 average target price
• Positive Sentiment: Roth Capital initiated or reiterated a “Buy” rating on Coya Therapeutics, adding to the constructive analyst coverage. Coya Therapeutics earns Buy rating from Roth Capital
• Neutral Sentiment: The estimate changes were not uniformly positive. HC Wainwright reduced its Q2 2027 EPS forecast to a loss of $0.48 from $0.46 and its Q3 2027 forecast to a loss of $0.40 from $0.39. Coya is still expected to remain unprofitable, with consensus estimates calling for a full-year loss.

Coya Therapeutics Stock Performance

NASDAQ:COYA opened at $4.86 on Friday. The stock’s fifty day moving average price is $4.90 and its two-hundred day moving average price is $4.68. Coya Therapeutics has a 52-week low of $3.71 and a 52-week high of $7.75. The company has a market cap of $114.01 million, a price-to-earnings ratio of -4.54 and a beta of 0.60.

Coya Therapeutics (NASDAQ:COYA) last released its earnings results on Tuesday, August 11th. The company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.07. The company had revenue of $0.24 million during the quarter, compared to analysts’ expectations of $0.13 million. Coya Therapeutics had a negative return on equity of 52.05% and a negative net margin of 270.22%. On average, equities analysts predict that Coya Therapeutics will post -1.34 EPS for the current fiscal year.

About Coya Therapeutics

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.